Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Negative urine or serum pregnancy test for women of childbearing potential\r\n* NOTE: females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must agree to adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Persons able to become pregnant must be willing to adhere to the scheduled pregnancy testing as required in the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only \r\n* NOTE: Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential are willing and able to adhere to the scheduled pregnancy testing as required by Celgene’s REVLIMID REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Women of childbearing potential: adhere to scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program
Lactating or pregnant patients or patients of reproductive potential not willing to use effective methods of contraception and adhere to the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Females of childbearing potential must be willing to adhere to the scheduled pregnancy testing as required by the Revlimid REMS program
Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the POMALYST REMS (TM) program
If assigned to receive lenalidomide and a female of reproductive potential, must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Women must not be pregnant or breast-feeding\r\n* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program\r\n* All females of childbearing potential must have a blood test within 2 weeks prior to registration to rule out pregnancy \r\n* Pregnancy testing is not required for post-menopausal or surgically sterilized women
Females of reproductive potential who will receive lenalidomide must adhere to the scheduled pregnancy testing as required in the Revlimid REMS(TM) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Female subject of childbearing potential must have a negative serum pregnancy 10-14 days prior to registration, and again within 24 hours prior to the first dose of lenalidomide; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of childbearing potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program; NOTE: This requirement only applies to patients randomized to Arm A
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the lenalidomide REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS)® program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program